DS
RVMD icon

David Shaw’s Revolution Medicines RVMD Stock Holding History

David Shaw’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.65M Buy
35,500
+10,500
+42% +$1.53M ﹤0.01% 2178
2026
Q1 		$2.43M Buy
+25,000
New +$2.52M ﹤0.01% 2761

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

David Shaw's RVMD Position: Q2 2026 in Review

David Shaw reduced its Revolution Medicines (RVMD) stake by 99% in Q2 2026, selling an estimated $148M and leaving 12,400 shares worth $2.32M. The position accounts for ﹤0.01% of the portfolio, ranked #3071.

David Shaw first reported a position in RVMD in Q1 2021 and has held it in 18 quarters since. The position peaked at $129M in Q4 2025. 688 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • David Shaw held 12,400 shares of Revolution Medicines worth $2.32M as of Q2 2026.
  • David Shaw sold 1,009,898 Revolution Medicines shares in Q2 2026, an estimated $148M.
  • Revolution Medicines made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #3071 holding.
  • David Shaw first reported a position in Revolution Medicines in Q1 2021 and has held it in 18 quarters since.
  • David Shaw's Revolution Medicines position peaked at $129M in Q4 2025.
  • 688 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.